Skip to main content
Hauptrubriken
CME Facharzt-Training Webinare Zeitschriften Bücher e.Medpedia Podcast
Service
Jobbörse Info & Hilfe
Fachgebiete
Anästhesiologie Allgemeinmedizin Arbeitsmedizin Augenheilkunde Chirurgie Dermatologie Gynäkologie und Geburtshilfe HNO Innere Medizin Kardiologie Neurologie Onkologie und Hämatologie Orthopädie und Unfallchirurgie Pädiatrie Pathologie Psychiatrie Radiologie Rechtsmedizin Urologie Zahnmedizin
Themen
Typ-2-Diabetes und Adipositas Klimawandel und Gesundheit Neues aus dem Markt COVID-19 Praxis und Beruf Seltene Erkrankungen GOÄ & EBM Panorama
Sammlungen
Kasuistiken Algorithmen & Infografiken Blickdiagnosen Arthropedia FlapFinder (für Dermatochirurgen) Videos Kongressberichterstattung Medizin für Apothekerinnen und Apotheker Für Ärztinnen und Ärzte in Weiterbildung Für Medizinstudierende

Live-Webinar "Urologie und Sexualmedizin in der Praxis"

Häufige urologisch-sexualmedizinische Themen in der Praxis sind das Thema des MMW-Webinars am 5. Juni von 17.30 bis 19 Uhr. Konkret geht es um die Frage, wann bei Harnwegsinfektionen auf Antibiotika verzichtet werden kann, und um ein Update zur Therapie von Libido- und Potenzstörungen des Mannes. Der dritte Vortrag behandelt sexuell übertragbare Krankheiten. Stellen Sie Ihre Fragen an die Experten und sammeln Sie 2 CME-Punkte. Jetzt gleich anmelden!
Erweiterte Suche
Anmelden
nach oben
Breast Cancer Research
Erschienen in: Breast Cancer Research 6/2004

01.12.2004 | Review

The changing global patterns of female breast cancer incidence and mortality

verfasst von: Freddie Bray, Peter McCarron, D Maxwell Parkin

Erschienen in: Breast Cancer Research | Ausgabe 6/2004

Einloggen, um Zugang zu erhalten

Abstract

One in ten of all new cancers diagnosed worldwide each year is a cancer of the female breast, and it is the most common cancer in women in both developing and developed areas. It is also the principal cause of death from cancer among women globally. We review the descriptive epidemiology of the disease, focusing on some of the key elements of the geographical and temporal variations in incidence and mortality in each world region. The observations are discussed in the context of the numerous aetiological factors, as well as the impact of screening and advances in treatment and disease management in high-resource settings.
Anhänge
Nur mit Berechtigung zugänglich
Literatur
1.
Ferlay J, Bray F, Pisani P, Parkin DM: GLOBOCAN 2000: Cancer Incidence, Mortality and Prevalence Worldwide. IARC Cancer Base No. 5. [1.0]. 2001, Lyon, France: IARC
2.
Parkin DM, Whelan SL, Ferlay J, Raymond L, Young J: Cancer Incidence in Five Continents. 1997, Lyon: IARC Press, VIII:
3.
Ziegler RG, Hoover RN, Pike MC, Hildesheim A, Nomura AM, West DW, Wu-Williams AH, Kolonel LN, Horn-Ross PL, Rosenthal JF, et al: Migration patterns and breast cancer risk in Asian-American women. J Natl Cancer Inst. 1993, 85: 1819-1827.CrossRefPubMed
4.
Geddes M, Parkin DM, Khlat M, Balzi D, Buiatti E: Cancer in Italian Migrants Populations. 1993, Lyon: IARC, IARC Scientific Publication No. 123
5.
Tyczynski J, Tarkowski W, Parkin DM, Zatonski W: Cancer mortality among polish migrants to Australia. Eur J Cancer. 1994, 30A: 478-484. 10.1016/0959-8049(94)90423-5.CrossRefPubMed
6.
Ries LAG, Eisner MP, Kosary CL, Hankey BF, Miller BA, Clegg L, Mariotto A, Feuer EJ, Edwards BK, eds: SEER Cancer Statistics Review, 1975–2001. 2004, Bethesda: National Cancer Institute
7.
Sankaranarayanan R, Parkin DM, Black RJ: Cancer Survival in Developing Countries. 1998, Lyon: IARC
8.
Coleman MP, Gatta G, Verdecchia A, Esteve J, Sant M, Storm H, Allemani C, Ciccolallo L, Santaquilani M, Berrino F: EUROCARE-3 summary: cancer survival in Europe at the end of the 20th century. Ann Oncol. 2003, 14 (Suppl 5): V128-V149. 10.1093/annonc/mdg756.CrossRefPubMed
9.
Peto R, Boreham J, Clarke M, Davies C, Beral V: UK and USA breast cancer deaths down 25% in year 2000 at ages 20–69 years. Lancet. 2000, 355: 1822-10.1016/S0140-6736(00)02277-7.CrossRefPubMed
10.
Bray F, Sankila R, Ferlay J, Parkin DM: Estimates of cancer incidence and mortality in Europe in 1995. Eur J Cancer. 2002, 38: 99-166. 10.1016/S0959-8049(01)00350-1.CrossRefPubMed
11.
Henderson BE, Ross R, Bernstein L: Estrogens as a cause of human cancer: the Richard and Hinda Rosenthal Foundation Award Lecture. Cancer Res. 1988, 48: 246-253.PubMed
12.
Moolgavkar SH, Stevens RG, Lee JA: Effect of age on incidence of breast cancer in females. J Natl Cancer Inst. 1979, 62: 493-501.PubMed
13.
European Network of Cancer Registries: EUROCIM Version 4.0. 2001, Lyon: European Network of Cancer Registries
14.
Botha JL, Bray F, Sankila R, Parkin DM: Breast cancer incidence and mortality trends in 16 European countries. Eur J Cancer. 2003, 39: 1718-1729. 10.1016/S0959-8049(03)00118-7.CrossRefPubMed
15.
Nab HW, Mulder PG, Crommelin MA, van der Heijden LH, Coebergh JW: Is the peak in breast cancer incidence in sight? A study conducted in the southeastern Netherlands. Eur J Cancer. 1994, 30A: 50-52.CrossRefPubMed
16.
Quinn M, Allen E: Changes in incidence of and mortality from breast cancer in England and Wales since introduction of screening. United Kingdom Association of Cancer Registries. BMJ. 1995, 311: 1391-1395.CrossRefPubMedPubMedCentral
17.
18.
Cancer Registry of Norway: Cancer in Norway; 2000. 2003, Oslo: Cancer Registry of Norway (Kreftregisteret)
19.
Zahl PH, Strand BH, Maehlen J: Incidence of breast cancer in Norway and Sweden during introduction of nationwide screening: prospective cohort study. BMJ. 2004,
20.
Zaridze DG, Basieva TH: Incidence of cancer of the lung, stomach, breast, and cervix in the USSR: pattern and trends. Cancer Causes Control. 1990, 1: 39-40.CrossRefPubMed
21.
Stevens RG, Moolgavkar SH, Lee JAH: Temporal trends in breast cancer. Am J Epidemiol. 1982, 115: 759-777.PubMed
22.
Ewertz M, Carstensen B: Trends in breast cancer incidence and mortality in Denmark, 1943–1982. Int J Cancer. 1988, 41: 46-51.CrossRefPubMed
23.
Rostgaard K, Vaeth M, Holst H, Madsen M, Lynge E: Age-period-cohort modelling of breast cancer incidence in the Nordic countries. Stat Med. 2001, 20: 47-61. 10.1002/1097-0258(20010115)20:1<47::AID-SIM613>3.0.CO;2-5.CrossRefPubMed
24.
Tretli S, Gaard M: Lifestyle changes during adolescence and risk of breast cancer: an ecologic study of the effect of World War II in Norway. Cancer Causes Control. 1996, 7: 507-512.CrossRefPubMed
25.
Persson I, Bergstrom R, Sparen P, Thorn M, Adami HO: Trends in breast cancer incidence in Sweden 1958–1988 by time period and birth cohort. Br J Cancer. 1993, 68: 1247-1253.CrossRefPubMedPubMedCentral
26.
Walter SD, Day NE: Estimation of the duration of a pre-clinical disease state using screening data. Am J Epidemiol. 1983, 118: 865-886.PubMed
27.
Hermon C, Beral V: Breast cancer mortality rates are levelling off or beginning to decline in many western countries: analysis of time trends, age-cohort and age-period models of breast cancer mortality in 20 countries. Br J Cancer. 1996, 73: 955-960.CrossRefPubMedPubMedCentral
28.
29.
Bornefalk A, Persson I, Bergstrom R: Trends in breast cancer mortality among Swedish women 1953–92: analyses by age, period and birth cohort. Br J Cancer. 1995, 72: 493-497.CrossRefPubMedPubMedCentral
30.
Lacey JV, Devesa SS, Brinton LA: Recent trends in breast cancer incidence and mortality. Environ Mol Mutagen. 2002, 39: 82-88. 10.1002/em.10062.CrossRefPubMed
31.
Wun LM, Feuer EJ, Miller BA: Are increases in mammographic screening still a valid explanation for trends in breast cancer incidence in the United States?. Cancer Causes Control. 1995, 6: 135-144.CrossRefPubMed
32.
Weir HK, Thun MJ, Hankey BF, Ries LA, Howe HL, Wingo PA, Jemal A, Ward E, Anderson RN, Edwards BK: Annual report to the nation on the status of cancer, 1975–2000, featuring the uses of surveillance data for cancer prevention and control. J Natl Cancer Inst. 2003, 95: 1276-1299. 10.1093/jnci/djg040.CrossRefPubMed
33.
MacMahon B: Temporal trends in breast cancer incidence. Am J Epidemiol. 1982, 116: 867-PubMed
34.
Smigel K: Breast cancer death rates decline for white women [news]. J Natl Cancer Inst. 1995, 87: 173-CrossRefPubMed
35.
National Cancer Institute of Canada: Canadian Cancer Statistics 1998. National Cancer Institute of Canada. 1998
36.
Holford TR, Roush GC, McKay LA: Trends in female breast cancer in Connecticut and the United States. J Clin Epidemiol. 1991, 44: 29-39. 10.1016/0895-4356(91)90198-I.CrossRefPubMed
37.
Tarone RE, Chu KC, Gaudette LA: Birth cohort and calendar period trends in breast cancer mortality in the United States and Canada. J Natl Cancer Inst. 1997, 89: 251-256. 10.1093/jnci/89.3.251.CrossRefPubMed
38.
Giles GG, Amos A: Evaluation of the organised mammographic screening programme in Australia. Ann Oncol. 2003, 14: 1209-1211. 10.1093/annonc/mdg326.CrossRefPubMed
39.
Armstrong W, Borman B: Breast cancer in New Zealand: trends, patterns, and data quality. N Z Med J. 1996, 109: 221-224.PubMed
40.
Smith CL, Kricker A, Armstrong BK: Breast cancer mortality trends in Australia: 1921 to 1994. Med J Aust. 1998, 168: 11-14.PubMed
41.
Hermon C, Beral V: Breast cancer mortality rates are levelling off or beginning to decline in many western countries: analysis of time trends, age-cohort and age-period models of breast cancer mortality in 20 countries. Br J Cancer. 1996, 73: 955-960.CrossRefPubMedPubMedCentral
42.
Wakai K, Suzuki S, Ohno Y, Kawamura T, Tamakoshi A, Aoki R: Epidemiology of breast cancer in Japan. Int J Epidemiol. 1995, 24: 285-291.CrossRefPubMed
43.
Nagata C, Kawakami N, Shimizu H: Trends in the incidence rate and risk factors for breast cancer in Japan. Breast Cancer Res Treat. 1997, 44: 75-82. 10.1023/A:1005726110649.CrossRefPubMed
44.
Minami Y, Tsubono Y, Nishino Y, Ohuchi N, Shibuya D, Hisamichi S: The increase of female breast cancer incidence in Japan: emergence of birth cohort effect. Int J Cancer. 2004, 108: 901-906. 10.1002/ijc.11661.CrossRefPubMed
45.
Parkin DM: Cancer in developing countries. Cancer Surveys. 1994, 19/20: 519-561.
46.
Coleman MP, Esteve J, Damiecki P, Arslan A, Renard H: Trends in Cancer Incidence and Mortality. 1993, Lyon: IARC
47.
Yeole BB, Kurkure AP: An epidemiological assessment of increasing incidence and trends in breast cancer in Mumbai and other sites in India, during the last two decades. Asian Pac J Cancer Prev. 2003, 4: 51-56.PubMed
48.
Seow A, Duffy SW, McGee MA, Lee J, Lee HP: Breast cancer in Singapore: trends in incidence 1968–1992. Int J Epidemiol. 1996, 25: 40-45.CrossRefPubMed
49.
Yang L, Parkin DM, Li L, Chen Y: Time trends in cancer mortality in China: 1987–1999. Int J Cancer. 2003, 106: 771-783. 10.1002/ijc.11300.CrossRefPubMed
50.
Chie WC, Chen CF, Lee WC, Chen CJ, Lin RS: Age-period-cohort analysis of breast cancer mortality. Anticancer Res. 1995, 15: 511-515.PubMed
51.
Leung GM, Thach TQ, Lam TH, Hedley AJ, Foo W, Fielding R, Yip PS, Lau EM, Wong CM: Trends in breast cancer incidence in Hong Kong between 1973 and 1999: an age-period-cohort analysis. Br J Cancer. 2002, 87: 982-988. 10.1038/sj.bjc.6600583.CrossRefPubMedPubMedCentral
52.
Echimane AK, Ahnoux AA, Adoubi I, Hien S, M'Bra K, D'Horpock A, Diomande M, Anongba D, Mensah-Adoh I, Parkin DM: Cancer incidence in Abidjan, Ivory Coast: first results from the cancer registry, 1995–1997. Cancer. 2000, 89: 653-663. 10.1002/1097-0142(20000801)89:3<653::AID-CNCR22>3.0.CO;2-Z.CrossRefPubMed
53.
Chokunonga E, Levy LM, Bassett MT, Mauchaza BG, Thomas DB, Parkin DM: Cancer incidence in the African population of Harare, Zimbabwe: second results from the cancer registry 1993–1995. Int J Cancer. 2000, 85: 54-59.CrossRefPubMed
54.
Parkin DM, Ferlay J, Hamdi-Cherif M, Sitas F, Thomas JO, Wabinga H, Whelan SL: Cancer in Africa: Epidemiology and Prevention. 2003, Lyon: IARC
55.
Wabinga HR, Parkin DM, Wabwire-Mangen F, Nambooze S: Trends in cancer incidence in Kyadondo County, Uganda, 1960–1997. Br J Cancer. 2000, 82: 1585-1592. 10.1054/bjoc.1999.1071.CrossRefPubMedPubMedCentral
56.
Pike MC, Krailo MD, Henderson BE, Casagrande JT, Hoel DG: 'Hormonal' risk factors, 'breast tissue age' and the age-incidence of breast cancer. Nature. 1983, 303: 767-770.CrossRefPubMed
57.
Lane-Claypon JE: A Further Report on Cancer of the Breasts, with Special Reference to its Associated Antecedent Conditions. 1926, London: HMSO, Report on Public Health and Medical Subjects No. 32
58.
Beral V: Breast cancer and hormone-replacement therapy in the Million Women Study. Lancet. 2003, 362: 419-427. 10.1016/S0140-6736(03)14065-2.CrossRefPubMed
59.
Heck KE, Pamuk ER: Explaining the relation between education and postmenopausal breast cancer. Am J Epidemiol. 1997, 145: 366-372.CrossRefPubMed
60.
Adams J, White M, Forman D: Are there socioeconomic gradients in stage and grade of breast cancer at diagnosis? Cross sectional analysis of UK cancer registry data. BMJ. doi:10.1136/bmj.38114.679387.AE (published 2 June 2004)
61.
Collaborative Group on Hormonal Factors in Breast Cancer: Breast cancer and hormonal contraceptives: collaborative reanalysis of individual data on 53 297 women with breast cancer and 100 239 women without breast cancer from 54 epidemiological studies. Lancet. 1996, 347: 1713-1727. 10.1016/S0140-6736(96)90806-5.CrossRef
62.
Armstrong B, Doll R: Environmental factors and cancer incidence and mortality in different countries, with special reference to dietary practices. Int J Cancer. 1975, 15: 617-631.CrossRefPubMed
63.
Hunter DJ, Spiegelman D, Adami HO, Beeson L, van den Brandt PA, Folsom AR, Fraser GE, Goldbohm RA, Graham S, Howe GR, et al: Cohort studies of fat intake and the risk of breast cancer – a pooled analysis. N Engl J Med. 1996, 334: 356-361. 10.1056/NEJM199602083340603.CrossRefPubMed
64.
Smith-Warner SA, Spiegelman D, Adami HO, Beeson WL, van den Brandt PA, Folsom AR, Fraser GE, Freudenheim JL, Goldbohm RA, Graham S, et al: Types of dietary fat and breast cancer: a pooled analysis of cohort studies. Int J Cancer. 2001, 92: 767-774. 10.1002/1097-0215(20010601)92:5<767::AID-IJC1247>3.0.CO;2-0.CrossRefPubMed
65.
Magnusson C, Baron J, Persson I, Wolk A, Bergstrom R, Trichopoulos D, Adami HO: Body size in different periods of life and breast cancer risk in post-menopausal women. Int J Cancer. 1998, 76: 29-34. 10.1002/(SICI)1097-0215(19980330)76:1<29::AID-IJC6>3.3.CO;2-1.CrossRefPubMed
66.
Bergstrom A, Pisani P, Tenet V, Wolk A, Adami HO: Overweight as an avoidable cause of cancer in Europe. Int J Cancer. 2001, 91: 421-430. 10.1002/1097-0215(200002)9999:9999<::AID-IJC1053>3.0.CO;2-T.CrossRefPubMed
67.
Hamajima N, Hirose K, Tajima K, Rohan T, Calle EE, Heath CW, Coates RJ, Liff JM, Talamini R, Chantarakul N, et al: Alcohol, tobacco and breast cancer – collaborative reanalysis of individual data from 53 epidemiological studies, including 58,515 women with breast cancer and 95,067 women without the disease. Br J Cancer. 2002, 87: 1234-1245. 10.1038/sj.bjc.6600596.CrossRefPubMed
68.
Shapiro S, Coleman EA, Broeders M, Codd M, de Koning H, Fracheboud J, Moss S, Paci E, Stachenko S, Ballard-Barbash R: Breast cancer screening programmes in 22 countries: current policies, administration and guidelines. International Breast Cancer Screening Network (IBSN) and the European Network of Pilot Projects for Breast Cancer Screening. Int J Epidemiol. 1998, 27: 735-742. 10.1093/ije/27.5.735.CrossRefPubMed
69.
International Agency for Research on Cancer: Breast Cancer Screening. 2002, Lyon: IARC Press
70.
McCann J, Stockton D, Day N: Breast cancer in East Anglia: the impact of the breast screening programme on stage at diagnosis. J Med Screen. 1998, 5: 42-48.CrossRefPubMed
71.
Hakama M, Pukkala E, Heikkila M, Kallio M: Effectiveness of the public health policy for breast cancer screening in Finland: population based cohort study. BMJ. 1997, 314: 864-867.CrossRefPubMedPubMedCentral
72.
Tabar L, Fagerberg G, Duffy SW, Day NE, Gad A, Grontoft O: Update of the Swedish two-county program of mammographic screening for breast cancer. Radiol Clin North Am. 1992, 30: 187-210.PubMed
73.
Kricker A, Farac K, Smith D, Sweeny A, McCredie M, Armstrong BK: Breast cancer in New South Wales in 1972–1995: tumor size and the impact of mammographic screening. Int J Cancer. 1999, 81: 877-880. 10.1002/(SICI)1097-0215(19990611)81:6<877::AID-IJC7>3.3.CO;2-6.CrossRefPubMed
74.
Blanks RG, Moss SM, McGahan CE, Quinn MJ, Babb PJ: Effect of NHS breast screening programme on mortality from breast cancer in England and Wales, 1990–8: comparison of observed with predicted mortality. BMJ. 2000, 321: 665-669. 10.1136/bmj.321.7262.665.CrossRefPubMedPubMedCentral
75.
Jatoi I, Miller AB: Why is breast-cancer mortality declining?. Lancet Oncol. 2003, 4: 251-254. 10.1016/S1470-2045(03)01037-4.CrossRefPubMed
76.
Chlebowski RT, Collyar DE, Somerfield MR, Pfister DG: American Society of Clinical Oncology technology assessment on breast cancer risk reduction strategies: tamoxifen and raloxifene. J Clin Oncol. 1999, 17: 1939-1955.PubMed
77.
Early Breast Cancer Trialists' Collaborative Group: Tamoxifen for early breast cancer: an overview of the randomised trials. Lancet. 1998, 351: 1451-1467. 10.1016/S0140-6736(97)11423-4.CrossRef
78.
Chu KC, Tarone RE, Kessler LG, Ries LA, Hankey BF, Miller BA, Edwards BK: Recent trends in US breast cancer incidence, survival, and mortality rates. J Natl Cancer Inst. 1996, 88: 1571-1579.CrossRefPubMed
79.
80.
Selby P, Gillis C, Haward R: Benefits from specialised cancer care. Lancet. 1996, 348: 313-318. 10.1016/S0140-6736(96)02482-8.CrossRefPubMed
81.
Collaborative Group on Hormonal Factors in Breast Cancer: Breast cancer and breastfeeding: collaborative reanalysis of individual data from 47 epidemiological studies in 30 countries, including 50302 women with breast cancer and 96973 women without the disease. Lancet. 2002, 360: 187-195. 10.1016/S0140-6736(02)09454-0.CrossRef
82.
Cuzick J, Powles T, Veronesi U, Forbes J, Edwards R, Ashley S, Boyle P: Overview of the main outcomes in breast-cancer prevention trials. Lancet. 2003, 361: 296-300. 10.1016/S0140-6736(03)12342-2.CrossRefPubMed
83.
Cuzick J: Aromatase inhibitors in prevention – data from the ATAC (arimidex, tamoxifen alone or in combination) trial and the design of IBIS-II (the second International Breast Cancer Intervention Study). Recent Results Cancer Res. 2003, 163: 96-103.CrossRefPubMed
84.
Feigelson HS, Henderson BE: Future possibilities in the prevention of breast cancer: role of genetic variation in breast cancer prevention. Breast Cancer Res. 2000, 2: 277-282. 10.1186/bcr69.CrossRefPubMedPubMedCentral
85.
van Geel AN: Prophylactic mastectomy: the Rotterdam experience. Breast. 2003, 12: 357-361. 10.1016/S0960-9776(03)00136-X.CrossRefPubMed
Metadaten
Titel
The changing global patterns of female breast cancer incidence and mortality
verfasst von
Freddie Bray
Peter McCarron
D Maxwell Parkin
Publikationsdatum
01.12.2004
Verlag
BioMed Central
Erschienen in
Breast Cancer Research / Ausgabe 6/2004
Elektronische ISSN: 1465-542X
DOI
https://doi.org/10.1186/bcr932

Weitere Artikel der Ausgabe 6/2004

Breast Cancer Research 6/2004 Zur Ausgabe

Article selection

Articles selected in September 2004

Research article

Genetic polymorphism in the manganese superoxide dismutase gene, antioxidant intake, and breast cancer risk: results from the Shanghai Breast Cancer Study

Research article

Proteotypic classification of spontaneous and transgenic mammary neoplasms

Research article

The Na+–H+exchanger-1 induces cytoskeletal changes involving reciprocal RhoA and Rac1 signaling, resulting in motility and invasion in MDA-MB-435 cells

Review

Endocrinology and hormone therapy in breast cancer: Aromatase inhibitors versus antioestrogens

Meeting report

American Society for Clinical Oncology 40th Annual Meeting, New Orleans, LA, 5–8 June 2004: breast cancer highlights

Neu im Fachgebiet Onkologie

Mehr Brustkrebs, aber weniger andere gynäkologische Tumoren mit Levonorgestrel-IUS

04.06.2024 Levonorgestrel Nachrichten

Unter Frauen, die ein Levonorgestrel-freisetzendes intrauterines System (IUS) verwenden, ist die Brustkrebsrate um 13% erhöht. Dafür kommt es deutlich seltener zu Endometrium-, Zervix- und Ovarialkarzinomen.

Bei seelischem Stress sind Checkpoint-Hemmer weniger wirksam

03.06.2024 NSCLC Nachrichten

Wie stark Menschen mit fortgeschrittenem NSCLC von einer Therapie mit Immun-Checkpoint-Hemmern profitieren, hängt offenbar auch davon ab, wie sehr die Diagnose ihre psychische Verfassung erschüttert

Antikörper mobilisiert Neutrophile gegen Krebs

03.06.2024 Onkologische Immuntherapie Nachrichten

Ein bispezifischer Antikörper formiert gezielt eine Armee neutrophiler Granulozyten gegen Krebszellen. An den Antikörper gekoppeltes TNF-alpha soll die Zellen zudem tief in solide Tumoren hineinführen.

Erhebliches Risiko für Kehlkopfkrebs bei mäßiger Dysplasie

29.05.2024 Larynxkarzinom Nachrichten

Fast ein Viertel der Personen mit mäßig dysplastischen Stimmlippenläsionen entwickelt einen Kehlkopftumor. Solche Personen benötigen daher eine besonders enge ärztliche Überwachung.

Update Onkologie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.

Newsletter bestellen
Bildnachweise